EUVIMEDEUVIMED entdecken
Crossref

The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Ming Sound Tsao, Adam Rosenthal, Andrew G Nicholson, Frank Detterbeck, Wilfried E E Eberhardt, Yolande Lievens, Eric Lim, Jose-Maria Matilla, Yasushi Yatabe, Pier Luigi Filosso, Ricardo Beyruti, Katherine K Nishimura und 6 weitere

Journal of Thoracic Oncology · 2025

DOI: 10.1016/j.jtho.2025.01.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thoracic Oncology, 2025. Verfasst von Ming Sound Tsao und 17 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada. Electronic address: ming.tsao@uhn.ca. Hauptthemen laut MEDLINE: Lung Neoplasms, Neoplasm Staging, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: International Association for the Study of Lung Cancer, AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Pulmonary high-grade neuroendocrine carcinoma (NEC) includes SCLC and large cell NEC (LCNEC). The seventh and eighth editions of the TNM classification for lung cancer confirmed the applicability of this staging system for SCLC. With the proposal of N2 and M1c subcategories for the ninth edition classification, we assessed the applicability to NECs. METHODS: The database included NEC cases diagnosed between January 2011 and December 2019. Eligible cases, with valid survival time and eighth edition TNM stage, were classified as pure SCLC, combined SCLC with NSCLC, and LCNEC. Survival was calculated using the Kaplan-Meier method, pairwise differences using a log-rank test, and prognostic groups using a Cox regression analysis. RESULTS: There were 6181 pure and combined SCLC and 697 LCNEC cases available. For SCLC, survival outcome analyses included 4453 cases with clinical stage and 583 with pathologic stage data. The corresponding numbers for LCNEC were 585 and 508. The SCLC data validated the ninth edition classification for lung cancer, including the proposed new subcategories, N2a, single-station ipsilateral mediastinal or subcarinal lymph node involvement, and N2b, involvement of multiple ipsilateral or subcarinal stations. The data also validated the subcategorization of M1c into M1c1 (multiple lesions in a single extrathoracic organ system) and M1c2 (involvement of multiple extrathoracic organ systems). The LCNEC data were insufficient for complete survival analysis, but the available data reported decreasing survival with increasing clinical and pathologic stages. CONCLUSIONS: The ninth edition TNM classification applies to patients with NEC and is the appropriate standard for use in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsNeoplasm StagingCarcinoma, NeuroendocrineHumansFemaleMaleMiddle AgedDatabases, FactualAgedSurvival RatePrognosisCarcinoma, Large Cell

Stichwörter der Autor:innen

IASLCLCNECLarge cell neuroendocrine carcinomaNeuroendocrine neoplasmSCLCSmall cell lung carcinoma

Autor:innen und Institutionen

  • Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada. Electronic address: ming.tsao@uhn.ca.
  • Cancer Research And Biostatistics, Seattle, Washington.
  • Department of Histopathology, Royal Brompton and Harefield NHS Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
  • Department of Thoracic Surgery, Yale University School of Medicine, New Haven, Connecticut.
  • Department of Medical Oncology, UniversitätsKlinikum Essen, Department of Thoracic Oncology, Ruhrlandklinik, Essen, Germany.
  • Department of Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium.

Förderung

  • International Association for the Study of Lung Cancer
  • AstraZeneca PLC

Zitieren

APA

Tsao, M. S., Rosenthal, A., Nicholson, A. G., Detterbeck, F., Eberhardt, W. E. E., Lievens, Y., Lim, E., Matilla, J. M., Yatabe, Y., Filosso, P. L., Beyruti, R., Nishimura, K. K., Travis, W. D., Osarogiagbon, R. U., Rami-Porta, R., Rusch, V., Asamura, H., & Members of the IASLC Staging and Prognostic Factors Committee, the Advisory Boards, and Participating Institutions (2025). The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2025.01.013

Vancouver

Tsao MS, Rosenthal A, Nicholson AG, Detterbeck F, Eberhardt WEE, Lievens Y, et al. The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology. 2025. doi:10.1016/j.jtho.2025.01.013

BibTeX
@article{Tsao2025,
  author = {Tsao, Ming Sound and Rosenthal, Adam and Nicholson, Andrew G and Detterbeck, Frank and Eberhardt, Wilfried E E and Lievens, Yolande and Lim, Eric and Matilla, Jose-Maria and Yatabe, Yasushi and Filosso, Pier Luigi and Beyruti, Ricardo and Nishimura, Katherine K and Travis, William D and Osarogiagbon, Raymond Uyiosa and Rami-Porta, Ramon and Rusch, Valerie and Asamura, Hisao and Members of the IASLC Staging and Prognostic Factors Committee, the Advisory Boards, and Participating Institutions, Members of the IASLC Staging and Prognostic Factors Committee, the Advisory Boards, and Participating Institutions},
  title = {The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer},
  journal = {Journal of Thoracic Oncology},
  year = {2025},
  doi = {10.1016/j.jtho.2025.01.013}
}
Kostenlos starten →